Kathmere Capital Management’s Biogen BIIB Stock Holding History

Kathmere Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Buy	7,285 +642	+10%	+$123K	0.08%	171
2026 Q1	$1.22M	Buy	6,643 +1,852	+39%	+$341K	0.08%	186
2025 Q4	$843K	Buy	4,791 +2,318	+94%	+$379K	0.06%	225
2025 Q3	$346K	Buy	2,473 +810	+49%	+$109K	0.02%	359
2025 Q2	$209K	Buy	+1,663	New	+$207K	0.02%	446
2024 Q1	–	Sell	-820	Closed	-$212K	–	320
2023 Q4	$212K	Sell	820 -87	-10%	-$21.4K	0.03%	269
2023 Q3	$233K	Hold	907	–	–	0.03%	229
2023 Q2	$258K	Buy	+907	New	+$270K	0.04%	192
2021 Q1	–	Sell	-362	Closed	-$89K	–	157
2020 Q4	$89K	Hold	362	–	–	0.02%	201
2020 Q3	$103K	Buy	+362	New	+$101K	0.03%	176
2020 Q1	–	Sell	-921	Closed	-$273K	–	86
2019 Q4	$273K	Buy	+921	New	+$256K	0.1%	81

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kathmere Capital Management's BIIB Position: Q2 2026 in Review

Kathmere Capital Management increased its Biogen (BIIB) stake by 9.7% in Q2 2026, buying an estimated $123K and bringing the position to 7,285 shares worth $1.57M. The position accounts for 0.08% of the portfolio, ranked #171.

Kathmere Capital Management first reported a position in BIIB in Q4 2019 and has held it in 11 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Kathmere Capital Management held 7,285 shares of Biogen worth $1.57M as of Q2 2026.
Kathmere Capital Management bought 642 Biogen shares in Q2 2026, an estimated $123K.
Biogen made up 0.08% of Kathmere Capital Management's portfolio in Q2 2026, its #171 holding.
Kathmere Capital Management first reported a position in Biogen in Q4 2019 and has held it in 11 quarters since.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.